Staburo At ICH E6 (R3) Training 

Jun 3, 2025
Staburo At ICH E6 (R3) Training

We were delighted to welcome two highly experienced trainers, Dr. Andreas Berk and Helge Bonaventura from InnovationTriologie, to our Munich office for an engaging hybrid training session on the updated ICH E6 (R3) guideline. The training offered a comprehensive look at both GCP basic principles and the key changes from ICH E6 (R2) to the new R3 version, making it valuable for colleagues at all levels of experience. 

The friendly and open atmosphere encouraged participants to ask interesting questions and share their perspectives, enriching the learning experience for everyone. 

A coffee break offered the chance to network and reflect on the morning’s content, and we enjoyed a relaxed lunch afterwards with the trainers, providing further opportunity for exchange in an informal setting. 

We would like to thank Dr. Andreas Berk and Helge Bonaventura for their expert guidance and Q&A opportunity after the session, and all attendees for their active participation.  

At Staburo, we prioritise maintaining awareness of evolving regulatory requirements, as they form a fundamental part of our commitment to quality and excellence in clinical research. 

More Articles

7th Staburo Health Data Science Summit 

7th Staburo Health Data Science Summit 

The 7th Staburo Health Data Science Summit brought together experts from the pharmaceutical and life sciences industries to explore the evolving role of biomarkers and data science in advancing precision medicine.  With contributions from leading organizations,...

read more
Staburo @ ISCB/GMDS Conference 2026

Staburo @ ISCB/GMDS Conference 2026

Staburo Team Selected to Present at ISCB/GMDS Conference 2026 We are pleased to share that Maria Stark, Senior Data Scientist, and the team representing Staburo in the GMDS Biostatistics Competition have been selected to present their work at the upcoming ISCB/GMDS...

read more
Biomarkers at Staburo

Biomarkers at Staburo

In 2024 at Staburo was about building momentum in the area Biomarkers. Deepening our engagement in the PSI Biomarker SIG, strengthening collaborations, and developing the ideas that would later become deliverables. In 2025, we developed and released ShadowVIMP, an R...

read more